Nancy Violeta Kim

Ms. Nancy Violeta Kim

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2005 in The American Journal of Medicine
Verified
Journal Article
Open access
EHEric Holmboe
Eric Holmboe
NKNancy Violeta Kim
Nancy Violeta Kim
SCSarah Cohen
Sarah Cohen
MCMaureen Curry
Maureen Curry
AEAnne Elwell
Anne Elwell
TMThomas P. Meehan
Thomas P. Meehan

7 February 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
NKNancy Violeta Kim
Nancy Violeta Kim
GMGemma McErlean
Gemma McErlean
SYSerena Yu
Serena Yu
IKIan Kerridge
Ian Kerridge
MGMatthew Greenwood
Matthew Greenwood
RLRichard De Abreu Lourenco
Richard De Abreu Lourenco
This scoping review summarizes the evidence regarding healthcare resource utilization (HRU) and costs associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study was conducted in accordance with the Joanne Briggs Institute methodology for scoping reviews. The PubMed, Embase, and Health Business Elite Electronic databases were searched, in addition to grey literature. The databases were searched from inception up to November 2022. Studies that reported HRU and/or costs associated with adult (≥18 years) allo-HSCT were eligible for inclusion. Two reviewers independently screened 20% of the sample at each of the 2 stages of screening (abstract and full text). Details of the HRU and costs extracted from the study data were summarized, based on the elements and timeframes reported. HRU measures and costs were combined across studies reporting results defined in a comparable manner. Monetary values were standardized to 2022 US Dollars (USD). We identified 43 studies that reported HRU, costs, or both for allo-HSCT. Of these studies, 93.0% reported on costs, 81.4% reported on HRU, and 74.4% reported on both. HRU measures and cost calculations, including the timeframe for which they were reported, were heterogeneous across the studies. Length of hospital stay was the most frequently reported HRU measure (76.7% of studies) and ranged from a median initial hospitalization of 10 days (reduced-intensity conditioning [RIC]) to 73 days (myeloablative conditioning). The total cost of an allo-HSCT ranged from $63,096 (RIC) to $782,190 (double umbilical cord blood transplantation) at 100 days and from $69,218 (RIC) to $637,193 at 1 year (not stratified). There is heterogeneity in the reporting of HRU and costs associated with allo-HSCT in the literature, making it difficult for clinicians, policymakers, and governments to draw definitive conclusions regarding the resources required for the delivery of these services. Nevertheless, to ensure that access to healthcare meets the necessary high cost and resource demands of allo-HSCT, it is imperative for clinicians, policymakers, and government officials to be aware of both the short- and long-term health resource requirements for this patient population. Further research is needed to understand the key determinants of HRU and costs associated with allo-HSCT to better inform the design and delivery of health care for HSCT recipients and ensure the quality, safety, and efficiency of care.

12 June 2013 in Journal of Hospital Medicine
Verified
Journal Article
Open access
PDF file
TLTara Lagu
Tara Lagu
HKHarlan M. Krumholz
Harlan M. Krumholz
KDKumar Dharmarajan
Kumar Dharmarajan
CPChohreh Partovian
Chohreh Partovian
NKNancy Violeta Kim
Nancy Violeta Kim
PLPeter K. Lindenauer
Peter K. Lindenauer
BACKGROUND: Because relative value unit (RVU)‐based costs vary across hospitals, it is difficult to use them to compare hospital utilization.OBJECTIVE: To compare estimates of hospital utilization using RVU‐based costs and standardized costs.DESIGN: Retrospective cohort.SETTING AND PATIENTS: Years 2009 to 2010 heart failure hospitalizations in a large, detailed hospital billing database that contains an itemized log of costs incurred during hospitalization.INTERVENTION: We assigned every item in the database with a standardized cost that was consistent for that item across all hospitals.MEASUREMENTS: Standardized costs of hospitalization versus RVU‐based costs of hospitalization.RESULTS: We identified 234 hospitals with 165,647 heart failure hospitalizations. We observed variation in the RVU‐based cost for a uniform “basket of goods” (10th percentile cost $1,552; 90th percentile cost of $3,967). The interquartile ratio (Q75/Q25) of the RVU‐based costs of a hospitalization was 1.35 but fell to 1.26 after costs were standardized, suggesting that the use of standardized costs can reduce the “noise” due to differences in overhead and other fixed costs. Forty‐six (20%) hospitals had reported costs of hospitalizations exceeding standardized costs (indicating that reported costs inflated apparent utilization); 42 hospitals (17%) had reported costs that were less than standardized costs (indicating that reported costs underestimated utilization).CONCLUSIONS: Standardized costs are a novel method for comparing utilization across hospitals and reduce variation observed with RVU‐based costs. They have the potential to help hospitals understand how they use resources compared to their peers and will facilitate research comparing the effectiveness of higher and lower utilization. Journal of Hospital Medicine 2013;8:373–379. © 2013 Society of Hospital Medicine

1 February 2012 in Ophthalmology
Verified
Journal Article
Closed access
SSSabah A. Shah
Sabah A. Shah
DMDale R. Meyer
Dale R. Meyer
EWEdward Wladis
Edward Wladis
JSJennifer A. Sivak-Callcott
Jennifer A. Sivak-Callcott
GMGeva Mannor
Geva Mannor
NKNancy Violeta Kim
Nancy Violeta Kim

16 May 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
NKNancy Violeta Kim
Nancy Violeta Kim
GMGemma McErlean
Gemma McErlean
SYSerena Yu
Serena Yu
IKIan Kerridge
Ian Kerridge
MGMatthew Greenwood
Matthew Greenwood
RLRichard De Abreu Lourenco
Richard De Abreu Lourenco
Allogeneic hematopoietic stem cell transplant (allo-HSCT) is an expensive and resource intensive procedure. This study aims to review the literature pertaining to healthcare resource utilization (HRU) and costs associated with allo-HSCT complications. The review followed the Joanna Briggs Institute methodology for scoping reviews. The PubMed, EMBASE, and Health Business Elite were searched in addition to the grey literature. Eligibility criteria included studies that reported HRU and/or costs associated with adult (≥18 years) allo-HSCT. Studies were categorized according to complications of allo-HSCT including graft-versus-host disease (acute and chronic GVHD) and infections (fungal, cytomegalovirus, virus-associated hemorrhagic cystitis, and acute respiratory tract infection). Commonly reported HRU and cost measures were extracted, including those associated with the direct management of allo-HSCT complications and intensive care unit (ICU) admissions. Reported costs were standardized to 2022 United States Dollars. Patients who experienced GVHD or infection post-transplant had an overall greater HRU including higher rates of hospitalization, hospital readmission, ICU admission, and longer length of stay compared to those patients who did not. Patients with severe or refractory GVHD and/or infection following allo-HSCT required greater healthcare intervention. This scoping review synthesizes the current literature on HRU and costs associated with post allo-HSCT complications. Patients who experienced post allo-HSCT complications had higher HRU and incurred higher costs overall, noting the variability across studies in their clinical context, reporting of HRU, and cost measures.